NCT02197975View on ClinicalTrials.gov

Randomized, Crossover Safety and Pharmacokinetics Study of PT010

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
COPD
Interventions
DRUG

PT010 Dose 1

PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.

DRUG

PT010 Dose 2

PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.

DRUG

Placebo MDI

Placebo MDI. Administered as 2 inhalations

Trial Locations (1)

21201

SNBL Clinical Pharmacology Center, Baltimore

Sponsors
All Listed Sponsors
lead

Pearl Therapeutics, Inc.

INDUSTRY